A compound according to Formula I, wherein R 1 is selected from the group consisting of -OH, OR a, and NR b R c; R a is selected from the group consisting of hydrogen, straight or branched chain (C 1 -C 6)alkyl, (C 3 -C 8)cycloalkyl, (C 3 -C 14)aryl, (C 3 -C 14)heterocycloalkyl-(C 1 -C 6)alkylene-, (C 3 -C 14)heteroaryl-(C 1 -C 6)alkylene-, and (C 3 -C 14)aryl(C 1 -C 6)alkylene-; R b and R c are each independently selected from the group consisting of H, -OH, straight or branched (C 1 -C 6)alkyl, -SO 2 -(C 1 -C 6)alkyl, (C 3 -C 14)aryl-SO 2 -, (C 3 -C 14)heterocycloalkyl-(C 1 -C 6)alkylene-, and (C 3 -C 14)heteroaryl-(C 1 -C 6)alkylene-; R 2 is selected from the group consisting of H, straight or branched (C 1 -C 6) alkyl, and (C 1 -C 6)alkyl-C -; W, X, Y, and Z are each independently selected from the group consisting of a bond, -C(R')(R''')-, -C(R'')2-, -CR"'-, -NR"'-, -N-, -O-, -C -, and -S-, wherein no more than three of W, X, Y, and Z simultaneously represent a bond; and no two adjacent members of W, X, Y, and Z are simultaneously -O-, -S-, -N-, or -NR'''-; l, m, n and p independently are integers between 0 and 2 inclusive, wherein at least one of l, m, n, or p is not 0; optionally represents one or more double bonds; R 3 and R 4 are each independently selected from hydrogen, straight or branched (C 1 -C 6)alkyl, and C -R', or R 3 and R 4 together with the boron atom to which they are bound form a 5- or 6-membered ring that is fully saturated, or partially saturated; D is selected from the group consisting of straight or branched (C 3 -C 5)alkylene, straight or branched (C 2 -C 8)alkenylene, straight or branched (C 2 -C 8)alkynylene, (C 3 -C 14)arylene, and (C 3 -C 14)cycloalkylene, wherein one or more -CH 2 - groups in D are optionally and independently replaced with a moiety selected from group the consisting of O, NR', S, SO, SO 2, and CR'R"; or wherein any two adjacent -CH 2 - groups optionally represent two members of a (C 3 -C 14)-cycloalkylenyl group; and wherein no two adjacent -CH 2 - groups simultaneously represent O, NR', S, SO, or SO 2; R', R" and R"' are each independently selected from the group consisting of H, OH, S R d, S 2 R d, (C 1 -C 8)alkyl, (C 3 -C 6)aryl, -NH 2, -NH(C 1 -C 6)alkyl, -N[(C 1 -C 6)alkyl] 2, -C NR d R e, -C (C 1 -C 6)alkyl, -C (C 3 -C 14)aryl, -C O(C 1 -C 6)alkyl, -C O(C 3 -C 14)aryl, (C 3 -C 6)cycloalkyl, (C 3 -C 14)heterocycloalkyl, -C (C 3 -C 14)heterocycloalkyl, (C 3 -C 14)heteroaryl, (C 3 -C 14)aryl-(C 1 -C 6)alkylene-, -C (C 3 -C 14)aryl-(C 1 -C 6)alkylene-, -C (C 3 -C 14)aryl, (C 3 -C 6)cycloalkyl-(C 1 -C 6)alkylene-, (C 3 -C 14)heteroaryl-(C 1 -C 6)alkylene-, (C 3 -C 14)heterocycle-(C 1 -C 6)alkylene-; and wherein any alkyl, alkylene, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more members selected from the group consisting of halogen, oxo, -COOH, -CN, -NO 2, -OH, -NR d R e, -NR g S 2 R h, (C 1 -C 6)alkoxy, (C 3 -C 14)aryl, (C 1 -C 6)haloalkyl and (C 3 -C 14)aryloxy; wherein R d, R e, R g, and R h are each independently selected from the group consisting of H, straight or branched (C 1 -C 6)alkyl, optionally substituted (C 3 -C 14)aryl(C 1 -C 6)alkylene-, optionally substituted (C 3 -C 14)aryl, (C 1 -C 6)hydroxyalkyl, (C 1 -C 6)aminoalkyl, H 2 N(C 1 -C 6)alkylene-, optionally substituted (C 3 -C 6)cycloalkyl, optionally substituted (C 3 -C 14)heterocycloalkyl, optionally substituted (C 3 -C 14)heteroaryl, optionally substituted (C 3 -C 14)aryl-(C 1 -C 6)alkylene-, NR'R"C -, and (C 3 -C 6)aryl-(C 3 -C 14)-cycloalkylene-, or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof; with the proviso that the compound according to Formula I is not 1-amine-2-(3-boronopropyl)cyclohexane carboxylic acid.